TROG 20.03 - AVATAR - TROG Cancer Research

By w.paterson
21 June, 2021
0 Comments

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

Primary Sponsor

Victorian Comprehensive Cancer Centre (VCCC)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

Final Accrual

Closing Date of Accrual

22 November 2022

Trial Chairperson

Dr Steven David, Peter MacCallum Cancer Centre, VIC

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research

27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

R2810-ONC-1788/TROG 17.11 – CPOST

ICR-CTSU/2015/15552/TROG 16.03 – CORE

Related Post

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work

TROG 20.03 – AVATAR

A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer

R2810-ONC-1788/TROG 17.11 – CPOST

ICR-CTSU/2015/15552/TROG 16.03 – CORE

Related Post

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work